{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:16:22Z","timestamp":1788966982555,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anemia is a common complication of chronic kidney disease (CKD). We evaluated the feasibility of collecting comprehensive data from medical charts for longitudinal assessment of anemia among pediatric patients receiving erythropoiesis-stimulating agents (ESAs) for anemia of CKD in the United Kingdom (UK) and United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective chart review study used an electronic case report form to collect data from medical records of pediatric patients treated with an ESA (as either an incident or a prevalent patient) from January 1, 2017\u2013December 31, 2018. Consecutive chart reviews were conducted from November 1\u2013December 20, 2021. Data collected included clinical characteristics, disease, and treatment management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 50 patients enrolled, 36 (72.0%) and 14 (28.0%) were from the UK and US, respectively; median (interquartile range) age was 9.0 (4.0\u201311.0) years, 22 (44.0%) were female and 28 (56.0%) were male. Median follow-up was 52.1\u2009weeks. The most common primary CKD etiology was congenital anomalies of the kidney\/urinary tract (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914, 28.0%). Twenty-three (46.0%) patients received dialysis at the index date and eight (16.0%) had a kidney transplant post-index date. Twenty-eight (56.0%) patients received iron treatment with their index-line ESA. The mean (standard deviation) baseline hemoglobin level was 10.0 (2.0) g\/dL. Twenty adverse events (AEs) were recorded in nine (18.0%) patients; all were serious and no inference was sought for attributability to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates feasibility of retrospectively extracting clinical characteristics, treatment history, and AEs from medical charts of pediatric patients with anemia of CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05188-2","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:36:17Z","timestamp":1787837777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of pediatric patients receiving erythropoiesis-stimulating agents for management of anemia of chronic kidney disease in the UK and US: a feasibility assessment using retrospective chart review"],"prefix":"10.1186","volume":"27","author":[{"given":"Sally","family":"Mountcastle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keele","family":"Wurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Amelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Fraeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Hunnicutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Cuadripani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukshana","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora Staines","family":"Urias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Hiemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"5188_CR1","doi-asserted-by":"publisher","unstructured":"Amanullah F, Malik AA, Zaidi Z. Chronic kidney disease causes and outcomes in children: perspective from a LMIC setting. PLoS One. 2022;17(6):e0269632. https:\/\/doi.org\/10.1371\/journal.pone.0269632.","DOI":"10.1371\/journal.pone.0269632"},{"issue":"5","key":"5188_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00467-022-05816-7","volume":"38","author":"J Harambat","year":"2023","unstructured":"Harambat J, Madden I. What is the true burden of chronic kidney disease in children worldwide? Pediatr Nephrol. 2023;38(5):1389\u201393. https:\/\/doi.org\/10.1007\/s00467-022-05816-7.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5188_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.kint.2015.10.014","volume":"89","author":"JR Ingelfinger","year":"2016","unstructured":"Ingelfinger JR, Kalantar-Zadeh K, Schaefer F, Tao Li PK, Garcia-Garcia G, Couser WG, et al. Averting the legacy of kidney disease\u2014focus on childhood. Kidney Int. 2016;89(3):512\u201318. https:\/\/doi.org\/10.1016\/j.kint.2015.10.014.","journal-title":"Kidney Int"},{"issue":"6","key":"5188_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.pcl.2022.07.010","volume":"69","author":"JS VanSickle","year":"2022","unstructured":"VanSickle JS, Warady BA. Chronic kidney disease in children. Pediatr Clinics N Am. 2022;69(6):1239\u201354. https:\/\/doi.org\/10.1016\/j.pcl.2022.07.010.","journal-title":"Pediatr Clinics N Am"},{"issue":"11","key":"5188_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrneph.2011.115","volume":"7","author":"MA Atkinson","year":"2011","unstructured":"Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol. 2011;7(11):635\u201341. https:\/\/doi.org\/10.1038\/nrneph.2011.115.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"5188_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/ckj\/sfac058","volume":"15","author":"G Bruce","year":"2022","unstructured":"Bruce G, Schulga P, Reynolds BC. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review. Clin Kidney J. 2022;15(8):1483\u2013505. https:\/\/doi.org\/10.1093\/ckj\/sfac058.","journal-title":"Clin Kidney J"},{"key":"5188_CR7","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Cases A: anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med. 2021;8:642296. https:\/\/doi.org\/10.3389\/fmed.2021.642296.","journal-title":"Front Med"},{"issue":"6","key":"5188_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00467-021-05145-1","volume":"37","author":"R Harada","year":"2022","unstructured":"Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K. Epidemiology of pediatric chronic kidney disease\/kidney failure: learning from registries and cohort studies. Pediatr Nephrol. 2022;37(6):1215\u201329. https:\/\/doi.org\/10.1007\/s00467-021-05145-1.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"5188_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2215\/CJN.05301107","volume":"4","author":"AO Staples","year":"2009","unstructured":"Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(1):48\u201356. https:\/\/doi.org\/10.2215\/CJN.05301107.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5188_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.clnesp.2021.11.031","volume":"47","author":"N Bhagat","year":"2022","unstructured":"Bhagat N, Dawman L, Naganur S, Tiewsoh K, Kumar B, Pratyusha K, et al. Impact of anemia on the cardiovascular status in children with chronic kidney disease: a pilot study. Clin Nutr ESPEN. 2022;47:283\u201387. https:\/\/doi.org\/10.1016\/j.clnesp.2021.11.031.","journal-title":"Clin Nutr ESPEN"},{"issue":"10","key":"5188_CR11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/ckj\/sfad097","volume":"16","author":"L Cirillo","year":"2023","unstructured":"Cirillo L, De Chiara L, Innocenti S, Errichiello C, Romagnani P, Becherucci F. Chronic kidney disease in children: an update. Clin Kidney J. 2023;16(10):1600\u201311. https:\/\/doi.org\/10.1093\/ckj\/sfad097.","journal-title":"Clin Kidney J"},{"key":"5188_CR12","unstructured":"Unites States renal data System Annual data. Report https:\/\/usrds-adr.niddk.nih.gov\/2023\/end-stage-renal-disease\/1-incidence-prevalence-patient-characteristics-and-treatment-modalities."},{"issue":"2","key":"5188_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","volume":"8","author":"HHL Wu","year":"2022","unstructured":"Wu HHL, Chinnadurai R. Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis (Basel). 2022;8(2):103\u201314. https:\/\/doi.org\/10.1159\/000521162.","journal-title":"Kidney Dis (Basel)"},{"issue":"5","key":"5188_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","volume":"53","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53(5):823\u201334. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.040.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"5188_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.xkme.2020.06.008","volume":"2","author":"B Cizman","year":"2020","unstructured":"Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, et al. Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era. Kidney Med. 2020;2(5):589\u201399.e1. https:\/\/doi.org\/10.1016\/j.xkme.2020.06.008.","journal-title":"Kidney Med"},{"issue":"7","key":"5188_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00467-016-3482-6","volume":"32","author":"A Vasudevan","year":"2017","unstructured":"Vasudevan A, Phadke K, Yap H-K. Peritoneal dialysis for the management of pediatric patients with acute kidney injury. Pediatr Nephrol. 2017;32(7):1145\u201356. https:\/\/doi.org\/10.1007\/s00467-016-3482-6.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5188_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3345\/cep.2022.01431","volume":"66","author":"YH Ahn","year":"2023","unstructured":"Ahn YH. Optimal hemodialysis treatment for pediatric kidney failure patients. Clin Exp Pediatr. 2023;66(3):125\u201326. https:\/\/doi.org\/10.3345\/cep.2022.01431.","journal-title":"Clin Exp Pediatr"},{"issue":"1","key":"5188_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12882-017-0687-2","volume":"18","author":"G Woodrow","year":"2017","unstructured":"Woodrow G, Fan SL, Reid C, Denning J, Pyrah AN. Renal Association clinical practice guideline on peritoneal dialysis in adults and children. BMC Nephrol. 2017;18(1):333. https:\/\/doi.org\/10.1186\/s12882-017-0687-2.","journal-title":"BMC Nephrol"},{"key":"5188_CR19","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portoles","year":"2021","unstructured":"Portoles J, Martin L, Broseta JJ, Cases A. Cases A: anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med. 2021;8:642296. https:\/\/doi.org\/10.3389\/fmed.2021.642296.","journal-title":"Front Med"},{"issue":"9","key":"5188_CR20","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Sch\u00f6mig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021;36(9):1616\u201328. https:\/\/doi.org\/10.1093\/ndt\/gfab191.","journal-title":"Nephrol Dial Transpl"},{"key":"5188_CR21","doi-asserted-by":"publisher","first-page":"1249492","DOI":"10.3389\/fphar.2023.1249492","volume":"14","author":"MU Haider","year":"2023","unstructured":"Haider MU, Furqan M, Mehmood Q. Daprodustat: a potential game-changer in renal anemia therapy\u2014A perspective. Front Pharmacol. 2023;14:1249492. https:\/\/doi.org\/10.3389\/fphar.2023.1249492.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5188_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527835","volume":"9","author":"J Li","year":"2023","unstructured":"Li J, Haase VH, Hao CM. Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia. Kidney Dis (Basel). 2023;9(1):1\u201311. https:\/\/doi.org\/10.1159\/000527835.","journal-title":"Kidney Dis (Basel)"},{"key":"5188_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/IJNRD.S401598","volume":"16","author":"D Fliser","year":"2023","unstructured":"Fliser D, Mata Lorenzo M, Houghton K, Ainsworth C, Blogg M, Gonz\u00e1lez de Antona S\u00e1nchez E, et al. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. IJNRD. 2023;16:115\u201329. https:\/\/doi.org\/10.2147\/IJNRD.S401598.","journal-title":"IJNRD"},{"key":"5188_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/IJNRD.S314313","volume":"14","author":"HC Hsu","year":"2021","unstructured":"Hsu HC, Norton GR, Peters F, Robinson C, Dlongolo N, Solomon A, et al. Association of post transplantation anaemia and persistent secondary hyperparathyroidism with diastolic function in stable kidney transplant recipients. IJNRD. 2021;14:211\u201323. https:\/\/doi.org\/10.2147\/IJNRD.S314313.","journal-title":"IJNRD"},{"key":"5188_CR25","doi-asserted-by":"publisher","unstructured":"Gafter-Gvili A, Ayalon-Dangur I, Cooper L, Shochat T, Rahamimov R, Gafter U, et al. Posttransplantation anemia in kidney transplant recipients: a retrospective cohort study. Med (Baltim). 2017;96(32):e 7735. https:\/\/doi.org\/10.1097\/MD.0000000000007735.","DOI":"10.1097\/MD.0000000000007735"},{"issue":"1","key":"5188_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12882-019-1244-y","volume":"20","author":"A Schechter","year":"2019","unstructured":"Schechter A, Gafter-Gvili A, Shepshelovich D, Rahamimov R, Gafter U, Mor E, et al. Post renal transplant anemia: severity, causes and their association with graft and patient survival. BMC Nephrol. 2019;20(1):51. https:\/\/doi.org\/10.1186\/s12882-019-1244-y.","journal-title":"BMC Nephrol"},{"key":"5188_CR27","doi-asserted-by":"publisher","first-page":"1170100","DOI":"10.3389\/fmed.2023.1170100","volume":"10","author":"Y Tang","year":"2024","unstructured":"Tang Y, Guo J, Zhou J, Wan Z, Li J, Qiu T. Risk factors and current state of therapy for anemia after kidney transplantation. Front Med. 2024;10:1170100. https:\/\/doi.org\/10.3389\/fmed.2023.1170100.","journal-title":"Front Med"},{"key":"5188_CR28","doi-asserted-by":"publisher","unstructured":"Sato Y, Noguchi H, Kubo S, Hisadome Y, Kaku K, Tajima S, et al. The safety and efficacy of daprodustat for recipients in peritransplant period: a single-center retrospective study on post-transplant anemia management in kidney transplantation. Transpl Int. 2025;38:15237. https:\/\/doi.org\/10.3389\/ti.2025.15237.","DOI":"10.3389\/ti.2025.15237"},{"issue":"3","key":"5188_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00467-015-3225-0","volume":"31","author":"F Schaefer","year":"2016","unstructured":"Schaefer F, Hoppe B, Jungraithmayr T, Klaus G, Pape L, Farouk M, et al. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatr Nephrol. 2016;31(3):443\u201353. https:\/\/doi.org\/10.1007\/s00467-015-3225-0.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"5188_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00467-006-0071-0","volume":"21","author":"BA Warady","year":"2006","unstructured":"Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2006;21(8):1144\u201352. https:\/\/doi.org\/10.1007\/s00467-006-0071-0.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"5188_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00467-017-3758-5","volume":"33","author":"BA Warady","year":"2018","unstructured":"Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, et al. De Novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2018;33(1):125\u201337. https:\/\/doi.org\/10.1007\/s00467-017-3758-5.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"5188_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12098-022-04318-6","volume":"90","author":"AC Chidambaram","year":"2023","unstructured":"Chidambaram AC, Krishnamurthy S, Parameswaran S, Sugumar K, Deepthi B. Etiology, comorbidities, and rate of progression of pediatric chronic kidney disease: a cohort study. Indian J Pediatr. 2023;90(7):647\u201353. https:\/\/doi.org\/10.1007\/s12098-022-04318-6.","journal-title":"Indian J Pediatr"},{"issue":"4","key":"5188_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10157-013-0859-8","volume":"18","author":"M Hattori","year":"2014","unstructured":"Hattori M, Uemura O, Hataya H, Ito S, Hisano M, Ohta T, et al. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan. Clin Exp Nephrol. 2014;18(4):634\u201341. https:\/\/doi.org\/10.1007\/s10157-013-0859-8.","journal-title":"Clin Exp Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05188-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:31:03Z","timestamp":1788964263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5188"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05188-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Some of the material discussed in this manuscript was previously presented as a poster at the Pediatric Academic Societies 2023 Annual Meeting (Mountcastle et al. \u201cBaseline characteristics and treatment of US\/UK pediatric patients with anemia of chronic kidney disease (CKD) on dialysis (D) or not on dialysis (ND) treated with erythropoiesis-stimulating agents (ESA): a retrospective chart review\u201d) and at the UK Kidney Week 2023 (Richards et al. \u201cLongitudinal availability and frequency of Hb measurements in UK and US paediatric patients with anaemia of chronic kidney disease (CKD) on dialysis (D) or not on dialysis (ND) treated with erythropoiesis-stimulating agents (ESA): a retrospective chart review\u201d).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM, KW, SC, ESU, and AR (Anna Richards) are employed by GSK and hold financial equities in GSK. AR (Alice Rouleau), NRB, and KF are employees of PPD, part of Thermo Fisher Scientific. JM was employed by GSK at the time of study conduct and holds financial equities in GSK, and is now an employee of Boehringer Ingelheim. JA, JH, and DW were employed by GSK at the time of study conduct and hold financial equities in GSK. TFH was employed by GSK at the time of study conduct. AK has no relevant disclosures. RS has received research grants and speaker honoraria from Amgen, Fresenius Medical Care, and Vitaflo.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"532"}}